| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3335505 | Transfusion and Apheresis Science | 2012 | 5 Pages |
Abstract
Extracorporeal photopheresis (ECP) is an established therapy for cutaneous T-cell lymphoma (CTCL). The objective of this study was to further explore the clinical efficacy of ECP combined with immunomodulatory agents.Eighteen patients with histologically proven CTCL were followed-up after therapy with ECP, mainly combined with interferon-α or bexarotene.A total of 61% of patients responded to therapy (n = 11; CR: 5, PR: 6). Median survival was 51 months, progression free survival was 28 months and response duration was 29 ± 23.9 months.ECP combined therapy was highly effective or had a palliative effect in CTCL resistant to previous treatments.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Marina P. Siakantaris, Panagiotis Tsirigotis, Niki Stavroyianni, Kimon V. Argyropoulos, Konstantinos Girkas, Vasiliki Pappa, Spiros Chondropoulos, Evangelia Papadavid, Ioanna Sakellari, Achilles Anagnostopoulos, Christina Antoniou, John Dervenoulas,